Buy OVID: Phase 1 Safety Win for OV329 and a Clear Path Into TSC and Infantile Spasms

Hook / Thesis

Ovid Therapeutics is a small-cap, clinical-stage biotech that just handed the market a tidy Phase 1 safety result for OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor, and backed it up with a $60 million PIPE to fund Phase 2 work and expansion into tuberous sclerosis complex (TSC) and infantile spasms (IS). The headline: no treatment-related adverse events at the 7 mg dose and no ophthalmic changes — an important point given historical safety concerns for this class.

At a current price of $2.75 and a market cap of about $513 million, the stock already reflects some optimism but still leaves room for upside if Ovid executes to a Phase 2 start and early readouts. I’m recommending a buy as a position trade (around 180 trading days) with a disciplined stop and a target that anticipates a successful Phase 2 launch or strong partnering interest.

Why the market should care

OV329 targets GABA-AT, the enzyme that breaks down GABA. Modulating GABA levels is a validated mechanism in epilepsy; what matters here is safety and tolerability. Older inhibitors showed efficacy but were plagued by side effects, including ophthalmic safety issues. Ovid’s Phase 1 announced on 03/18/2026 showed no treatment-related adverse events at the 7 mg dose and no ophthalmic changes, addressing a major clinical risk that has constrained the class.

Beyond the mechanism, Ovid’s plan to expand OV329 into TSC and infantile spasms is strategic: both are high-unmet-need, often pediatric indications where an effective, well-tolerated GABAergic therapy could command premium pricing and rapid uptake. The company also has a small-molecule KCC2 activator portfolio and other early assets that add optionality, but OV329 is the clear near-term value driver.

Snapshot and financial framing

Note on cash runway: enterprise value sits at roughly $393M versus a market cap near $513M, implying roughly $120M of net cash on the balance sheet after accounting for market cap differences. That implied cash plus the $60M PIPE announced on 03/18/2026 provides a concrete near-term funding cushion to execute Phase 2 and the planned indication expansions without immediate, large-scale dilution.

Technical and market context

The tape is constructive: 10-day SMA ~$2.594, 20-day SMA ~$2.453, RSI ~60.7 and a bullish MACD histogram. Volume has been elevated — today’s intraday range was $2.49 to $2.82 and volume near 3.3M shares — showing investor interest post-news. Short interest has risen at times (recent settlements show short interest as high as ~11.86M shares on 06/15/2026), which increases both downside volatility and the potential for squeezes around positive catalysts.

Valuation framing

At a $513M market cap the stock is priced for clinical development and a pathway to meaningful specialty sales if the drug proves safe and effective in pivotal studies for pediatric indications. For context, epilepsy and rare pediatric epilepsy assets that clear early safety and show signals often trade to multiples in the high single digits to low double digits of revenue potential post-approval. Ovid’s valuation is effectively a forward bet on OV329’s ability to clear Phase 2 safely and create a clear path into TSC and IS.

Put differently: this is a binary, development-stage valuation. If OV329 advances on schedule and generates encouraging Phase 2 signals or an attractive partnership, the stock could re-rate toward mid-single-digit multiples of current price. If the program stalls, downside is significant, given the company’s limited commercial-stage assets.

Key catalysts (what to watch)

• 03/18/2026 - PIPE announcement and Phase 1 topline: the market has already reacted to the initial safety readout and funding. Execution of the planned use of proceeds (trial starts and enrollment) will matter for the next 3-9 months.
• Planned Phase 2 initiation dates and trial design details for OV329 in focal epilepsy - watch for trial start announcements and enrollment milestones.
• Regulatory and pediatric study discussions - early interactions or agreements with regulators on pediatric development plans would materially de-risk the TSC and IS expansions.
• Scientific conferences and investigator-led updates - presentations at medical meetings can provide early signal data or supportive biomarker results.

Trade plan (actionable)

Thesis: Buy for a position trade targeting clear clinical and funding execution over a medium-long window.

• Entry price: $2.75
• Stop loss: $2.10 (a break and close below $2.10 indicates loss of the recent support band and increased risk of further downside)
• Target: $5.00 (reflects a successful Phase 2 initiation and visible progress on TSC/IS expansion or meaningful partnering interest within the trade window)
• Horizon: position (180 trading days). I expect this timeframe gives enough runway for trial initiation, early enrollment updates or partnership conversations that would re-rate the stock. If a meaningful data readout occurs earlier, I would consider tightening the stop or taking partial profits.

Why these levels? Entry at $2.75 captures momentum after the Phase 1 safety readout. The stop at $2.10 limits downside to roughly 23% and sits below recent short-term support while allowing for normal post-news pullbacks. The $5.00 target assumes the market prices in a visible Phase 2 program or partnership interest; that target equates to roughly a 90% upside from entry and is appropriate for a high-risk, binary developmental story.

Risks and counterarguments

• Clinical failure or safety surprises: OV329’s Phase 1 result was limited to healthy volunteers and a 7 mg dose cohort; later-phase safety and efficacy may reveal adverse effects not seen in Phase 1. Ophthalmic safety concerns historically weigh on this class even if early signals look clean.
• Execution/delay risk: Biotech timelines slip. If Ovid delays Phase 2 starts or enrollment stalls, the stock could trade lower despite the PIPE. Development timelines and regulatory interactions are unpredictable.
• Dilution risk: Even with the $60M PIPE, additional capital raises could be necessary to fund multiple indication trials, which would dilute existing shareholders and compress per-share value.
• Competitive and commercial risk: The epilepsy and rare pediatric epilepsy space is crowded with competitors and complementary approaches. Superior alternatives could limit OV329’s market share even if it reaches approval.
• Market skepticism reflected in short interest: Rising short interest and heavy short-volume days indicate a portion of the market is skeptical; that can magnify downside if catalysts disappoint.

Counterargument

One could reasonably argue that the stock already prices in the Phase 1 result and PIPE; therefore, there’s a risk-reward asymmetry that favors sellers. The implied cash runway, while appearing healthy when inferred from enterprise value, still needs to fund multi-indication Phase 2 programs and pediatric work, which are expensive. If the market reads the PIPE as merely delaying an inevitable larger capital raise, the stock could trade sideways or lower despite clinical progress.

What would change my mind

I would downgrade or exit this position if Ovid announces materially negative safety signals in OV329 Phase 2, a delay that pushes meaningful readouts beyond the 180 trading-day window, or an unexpectedly large capital raise that meaningfully dilutes shareholders without a commensurate acceleration in development or partnering. Conversely, early Phase 2 enrollment success, a strong interim signal, or a partnership/licensing deal would validate the thesis and likely prompt adding to the position or moving up targets.

Conclusion

Ovid Therapeutics is a high-risk, high-upside development-stage name where a clean Phase 1 safety readout for OV329 and a $60M PIPE provide a credible path to Phase 2 execution and expansion into TSC and IS. At $2.75 the risk/reward looks attractive for a position trade targeting $5.00 over approximately 180 trading days, provided the company executes on trial starts and early development milestones. Use a disciplined stop at $2.10 to limit downside and monitor enrollment, safety updates, and any partnering chatter as primary upside catalysts.

Entry $2.75 / Stop $2.10 / Target $5.00 - Position trade (180 trading days)